WO1996025057A1 - Nichtalkoholisches getränk, seine verwendung sowie verfahren und vorrichtung zur herstellung des getränks - Google Patents
Nichtalkoholisches getränk, seine verwendung sowie verfahren und vorrichtung zur herstellung des getränks Download PDFInfo
- Publication number
- WO1996025057A1 WO1996025057A1 PCT/EP1996/000595 EP9600595W WO9625057A1 WO 1996025057 A1 WO1996025057 A1 WO 1996025057A1 EP 9600595 W EP9600595 W EP 9600595W WO 9625057 A1 WO9625057 A1 WO 9625057A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxygen
- liquid
- pipe system
- drink
- mixing unit
- Prior art date
Links
- 235000019520 non-alcoholic beverage Nutrition 0.000 title claims abstract description 5
- 238000000034 method Methods 0.000 title claims description 17
- 230000008569 process Effects 0.000 title claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 77
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 76
- 239000001301 oxygen Substances 0.000 claims abstract description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000007788 liquid Substances 0.000 claims abstract description 37
- 239000007789 gas Substances 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 29
- 108700024047 pangamic acid Proteins 0.000 claims description 26
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 claims description 24
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 claims description 24
- 229940055705 pangamic acid Drugs 0.000 claims description 24
- 235000013361 beverage Nutrition 0.000 claims description 15
- MKVDFFROCUECAJ-CKDSBIORSA-M sodium;(2r,3s,4r,5r)-6-[2-(dimethylamino)acetyl]oxy-2,3,4,5-tetrahydroxyhexanoate Chemical compound [Na+].CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O MKVDFFROCUECAJ-CKDSBIORSA-M 0.000 claims description 11
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 2
- 229960003144 calcium pangamate Drugs 0.000 claims 2
- JWLAOERSRUNGEF-JQVJEGKNSA-L calcium;(2r,3s,4r,5r)-6-[2-(dimethylamino)acetyl]oxy-2,3,4,5-tetrahydroxyhexanoate Chemical compound [Ca+2].CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O JWLAOERSRUNGEF-JQVJEGKNSA-L 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 23
- 102000007330 LDL Lipoproteins Human genes 0.000 description 23
- 239000010949 copper Substances 0.000 description 15
- 239000011734 sodium Substances 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001993 dienes Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- -1 lipid hydroperoxides Chemical class 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000550081 Renata Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229940097156 peroxyl Drugs 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000022743 cholesterol storage Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000005471 saturated fatty acid group Chemical group 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/54—Mixing with gases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Non-alcoholic beverage its use and method and device for producing the beverage
- the invention relates to a table water, medicinal water or the like non-alcoholic beverage.
- pangamic acid in pectanginous complaints and in liver chirrosis is also known (Hunnius, Pharmaceutical Dictionary, 6th edition).
- the invention is based on the object of providing a simple and inexpensive means with which hypoxic conditions in the cells and the cell structure of the organism can be permanently eliminated.
- the invention proposes a table water, medicinal water or similar non-alcoholic water-based drink which, in addition to its predetermined or natural oxygen content, expediently contains at least 10 mg / 1 dissolved oxygen and at least 0.5 mg / 1 dissolved panamic acid Contains form of their sodium and / or calcium salt.
- Eble, Lohr and Wannen ⁇ macher demonstrate that the oral administration of water enriched with oxygen in a simple manner increases the therapy resistance of hypoxic areas in larger areas Can overcome tumors. Thereafter it appears to be proven that oral administration of oxygenated water high oxygen partial pressure in the tissue is reached.
- tumors that have pO values that are smaller than the venous pO 2 value have a reduced one
- Radio sensitivity A rapid drop in radio sensitivity is observed at pO concentrations of 0-30 mmHg. An oxygen concentration of 0.5% (or 3 mmHg) reduces the relative radio sensitivity to 50% (Fig.l). According to FIG. 1, a reduced cellular radiation sensitivity is observed when the pO 2 value on the cell drops below 30 mmHg.
- FIG. 2 shows that there is a significant increase in the mean and median pO value after oral administration of oxygenated water.
- a double administration of oxygenated water with pO measurement led to a spontaneous increase in the oxygen content in the tumor.
- the mean values of the same measuring path (20 measuring points) in FIGS. 2 and 3 are noted as a stair curve.
- the agent according to the invention therefore on the one hand increases the oxygen supply for the cells and on the other hand improves the usability of oxygen due to its pangamic acid content by appropriately activating the substances responsible for the oxygen transport. This effectively counteracts a hypoxic milieu or the development thereof, so that complaints, which ultimately have their cause in a cellular undersupply of oxygen, are alleviated or even eliminated after administration of the agent according to the invention.
- Circulatory disorders and vasoconstriction are among the most widespread diseases in the industrialized countries.
- Vascular occlusions and blood vessel diseases conditions are based on the fact that very different influences strain the human metabolism and redirect it in certain areas.
- Arteriosclerosis can be called a civilization disease insofar as it is triggered or aggravated by typical citizenship factors.
- LDL low density lipoprotein
- LDL oxidative modification of LDL increases its atherogenic potential.
- the changed receptor affinity is of great importance.
- the LDL particles are taken up in an uncontrolled manner via scavenger receptors in macrophages and smooth muscle cells. The result is subendothelial cholesterol storage in foam cells.
- Oxidized LDL also triggers the formation of autoantibodies, resulting immune complexes are also taken up by macrophages.
- Circulatory monocytes which are influenced by chemotacticity differentiate into tissue macrophages and are immobilized.
- Oxidized LDL induces the expression of "vascular cell adhesion molecule" (VCAM) on monocytes and endothelial cells, which attach to the beginning lesions.
- VCAM vascular cell adhesion molecule
- the oxidation process is a lipid peroxidation process triggered by free radicals.
- the aldehydic products of the lipid-hydroperoxide decay are responsible for the modification of the apoprotein.
- FIG. 4 shows the characteristic three-phase curve which arises when the diene formation is monitored spectrophotometrically at 234 nm during the Cu (II) oxidation of an LDL solution.
- B propagation phase
- the maximum diene formation rate is reached.
- C the decomposition phase
- the oxidized substrates break down into aldehydes and other products such as hydrocarbon gases, epoxies and alcohols.
- Lipoxygenases catalyze the deoxygenation of poly fatty acids to form fatty acid hydroperoxides. Yiä-Herttula et al. (1995) transferred the 15-lipoxygenase gene into arterial walls of rabbits. In combination with a slight hypercholesterolemia, specific LDL oxidation products could be detected in the artery wall.
- ceruloplasmin also has prooxidative activities against LDL (Ehrenwald et al., 1994).
- the hydrogen abstraction is gene in the carbon chain in the order polyunsaturated fatty acid side chain> monounsaturated fatty acid side chain> saturated fatty acid side chain.
- a reaction with oxygen which is present as a lipophilic molecule enriched in hydrophobic regions of membranes and lipoproteins, gives conjugated diene-peroxyl radicals (LOO * ).
- Lipid peroxides are formed from the attack on intact fatty acid side chains (LH) with the formation of new carbon-centered radicals (L ' ). This autocatalytic chain reaction continues until the substrates are used up; lack of oxygen is often a limiting factor. Chain termination options exist in the reaction of antioxidants or other chain-terminating molecules (A ' ) as competition to the fatty acid side chains, and in reactions of peroxyl radicals with themselves or with other carbon-centered radicals. The chemical principles of lipid peroxidation are outlined in FIG.
- pangamic acid is an excellent protective substance for LDL.
- pangamic acid for the LDL can be seen by comparing the curve shown for solid lines for non-oxidized LDL with the dash-dotted curves for 50 mg / 1 pangamic acid content and 100 mg / 1 panganoic acid content, which run below the solid curve.
- the cations of the beverage according to the invention can be one or more of the ionized elements lithium, sodium, potassium, ammonium, magnesium, calcium, strontium, barium, manganese, iron, the anions residues from the group fluoride, chloride, bromide, iodide, nitrate , Sulfate, hydrogen phosphate, hydrogen carbonate and others.
- Silicic acid and / or boric acid are particularly suitable as undissociated substances. It is advisable to provide up to 85 mg / 1 dissolved oxygen for the additional oxygen content. As dissolved pangamic acid there is a content of up to 240 mg / 1.
- an oxygen-containing gas is drawn into the aqueous liquid flowing at high speed, for example a customary still mineral water, and the mixture formed is rotated along at least one path.
- This enables, for example, drinking water to be enriched with at least 10 mg / 1 and even more than 85 mg / 1 of dissolved oxygen. This value is considerably higher than the known atmospheric oxygen saturation concentration of oxygen in water.
- panamic acid for example in the form of its sodium and / or calcium salt, is dissolved in the liquid thus obtained in an amount of at least 0.5 mg / 1, preferably up to 240 mg / 1.
- the finished agent has an excellent shelf life over a period of at least one year without significant oxygen escaping from the mixture.
- the preferred measure is to draw the gas into the liquid via several parallel channels. Furthermore, it is advisable to feed the mixture back into the circuit after rotation and to subject it again to the treatment described, in order in this way to achieve a stable and an even higher enrichment of oxygen.
- Pangamic acid can then be added to the emerging mixture. It is particularly advantageous to use a serpentine pipe system as the path, which results in a shorter dwell time. The efficiency is increased if the mixture is passed through several paths connected in series. Due to the easy solubility of pangamic acid in water, the agent according to the invention can also be obtained by first dissolving the pangamic acid or the panamate in the stated amount in the aqueous liquid, that is to say the mineral water, and then the Desired enrichment of oxygen is carried out as explained.
- a device which is suitable for producing the beverage according to the invention and for carrying out the above-mentioned method has a pump which is connected to a liquid source and which feeds an aqueous liquid at high speed to a mixing unit which supplies oxygen emitting gas source is connected, the mixing unit being followed by a serpentine pipe system, behind which a metering device for the metered addition of pangamic acid and behind the metering device a tap for the beverage are provided.
- a dosing device for the dosed addition of panamic acid is assigned to a liquid source, and that a pump connected to the liquid source is an aqueous, mixed with panamic acid at high speed supplies a mixing unit, which is connected to an oxygen-emitting gas source, and that the mixing unit is followed by a serpentine pipe system, behind which a tap for the beverage is provided.
- a rotary nozzle can be provided between the mixing unit and the pipe system.
- the mixing unit can advantageously have a plurality of mixing nozzles which are connected in parallel to the gas source.
- An oxygen sensor which detects the oxygen content of the mixture and which controls a downstream extraction valve is expediently arranged at the tap.
- a central control system is recommended, in which the output signals of the oxygen sensor representing the oxygen content are compared with an adjustable target value, and which controls the extraction valve and the control valve accordingly.
- FIG. 1 shows the radio sensitivity as a function of tissue oxygenation
- FIG. 2 and 3 chronologically measured PO values before and after oral administration of oxygenated water, designated POS;
- FIG. 4 characteristic phases of the C (II) -induced LDL oxidation;
- FIG. 5 shows schematically the processes involved in lipid peroxidation
- FIG. 6 shows the absorption over the reaction time of LDL as a function of different pangamic acid concentrations
- FIG. 7 schematically shows a device for producing the beverage according to the invention
- FIG. 8 shows a detail from the device according to FIG. 7;
- FIG. 9 shows a partial axial section of a mixing unit from the device according to FIG. 7;
- FIG. 10 shows the top view of the cross section X-X through the mixing unit according to FIG. 9;
- FIG. 13 shows a partial axial section through a rotary nozzle from the device according to FIGS. 7 and FIG. 14 shows a detail, enlarged, from the rotary nozzle according to FIG. 13.
- the water from the Renata source in 64757 Rothenberg in the Odenwald, Germany is first used.
- An analysis of this water carried out on May 24, 1995 led to the following results:
- FIGS. 7 to 14 illustrate, as an example, a device which is suitable for producing the drink, starting from the mineral water from the Renata spring.
- a gas line 11, 13, 15, 17 leads from an oxygen source, not shown, at 1, which can be ambient air or an oxygen tank with a reducing valve, which has a gas meter 14, a magnetic shut-off valve 16 and a check valve 18 to a mixing unit 20, in which several, for example seven, mixing nozzles are connected in parallel to the downstream side of the check valve 18.
- the spring water of the Renata source is fed to a tank 26 via a line 21 and a water meter 24.
- a feed line 71 opens into the tank 26 from a metering device 70 containing a supply of sodium pangamate, which feeds metered amounts of sodium pangamate via the feed line 71 into the spring water contained in the tank 26.
- water is supplied to a pump 10 via line 27, in which a shut-off valve 28 is seated, the pump output of which can be regulated up to a pressure of approximately 16 bar.
- the liquid of approximately 12 bar (absolute) emerging from the pump 10 at a high flow rate passes via line 29 into the mixing unit 20, in which the sodium particle dissolved by the flowing liquid or the dissolved 15
- Source water containing gamat in line 13 produces a negative pressure of oxygen, which is fed in at a pressure of about 1 bar (absolute), is drawn into the water in fine distribution through the aforementioned mixing nozzles.
- the mixing unit 20 is followed by a path for the oxygen / water mixture emerging from it, which path comprises a rotary nozzle 22 and a pipe system 30 in series.
- the oxygen / water mixture is directed into a circular path, the axis of which is essentially horizontal.
- the rotating mixture emerging from a fine nozzle opening passes via line 23 into the pipe system 30, the coils of which are arranged in a cone standing on the tip or in a cylinder (FIG. 8) with a vertical axis.
- the mixture leaves the pipe system 30 via line 31, in which a valve 32 is arranged.
- the outflow line 37 of the solenoid valve 32 leads to a solenoid valve 34, which is the input valve to a series circuit comprising a pump 36, a further mixing unit 46, a further rotary nozzle 38 and a further pipe system 40.
- the units 46, 34, 36, 38 and 40 correspond to the solenoid valve 28, the pump 10, the mixing unit 20, the rotary nozzle 22 and the pipe system 30 from the upstream arrangement and are constructed and designed in the same way as this.
- a line 39 leading the gas of 1 bar (absolute) pressure opens into the further mixing unit 46, which line is connected to line 15 and is equipped with a shut-off solenoid valve 16a and a check valve.
- a branch line 33 from line 37 leads via a solenoid valve 44 and a further line 35 to a point 50, to which one of the coils of the 16
- At point 50 is the electrode of an oxygen sensor 56, which detects the oxygen content of the mixture arriving at point 50 and feeds output signals representing the oxygen content to a central control 60 via a control line 67.
- a motor valve 52 Downstream of the point 50 there is a motor valve 52 in a line 51.
- the line 51 opens into a storage container 54 for the finished mixture, from which the water enriched with the desired oxygen content can be taken off at the tap 55 via line 53.
- the liquid-carrying lines of the device can be emptied via an outlet line 59 connected to the bottom of the container 54, in which a magnetic shut-off valve 58 is located, and via an outlet line 61 coming from the bottom of the tank 26 and equipped with a shut-off solenoid valve 64.
- Gas which collects and is practically pure oxygen above the water level of the container 54 can be fed into the gas line 15 via a line 57 and fed back to the mixing units 20, 46.
- bypass line 63 with a magnetic valve 62 that opens from the upstream side of the solenoid valve 28 into the line that leads from the valve 34 to the pump 36.
- the system described permits several modes of operation.
- a first mode of operation (series connection)
- the solenoid valve 16 and the corresponding valve 16a in the line 39 as well as the valves 28, 32, 34 and 42 are open, while the valves 62 and 44 are closed.
- the motor valves 52 and 66 regulate the inflow of the finished mixture into the container 54 and the backflow into the tank 26 via signals from the oxygen probe 56. Therefore, the water withdrawn from the pump 26 by the pump 10 in the mixing units 20 and 46 oxygen is drawn in from line 15 and the mixture is set in rotation along paths 22, 30 and 38, 40.
- the pump 36 is set by the control 60 in such a way that it compensates for the pressure loss in the water flowing through the mixing unit 20 and the rotating nozzle 22 and the pipe system and thus produces the same flow rate in front of the mixing unit 46 as that of the Pump 10 in line 29 generated flow rate.
- the oxygen sensor 56 measures the oxygen concentration of the mixture arriving from the pipe system 40 via the valve 42 at the point 50 and supplies an output signal representing the oxygen content at the point 50 to the controller 60 via a signal line 67. There, this output signal is transmitted with a Signal compared, which is representative of a setpoint of the oxygen concentration set in the controller 60.
- the control 60 closes the motor valve 66 and opens the motor valve 52.
- the finished mixture then reaches the storage container 54 and can flow out this can be removed via line 53 at the tap.
- the electronic water meter 24 sends a signal representing the amount of the spring water flowing through it to the control 60 via line 72, which sends a metering signal to the metering device 70 via output line 73.
- the metering device 70 then gives a quantity of sodium pangamate to the tank 26 via the feed line 71, which is proportional to the amount of spring water detected by the water meter and is dimensioned according to the desired concentration of sodium pangamate in the water contained in the tank 26.
- the sodium panate can be added to the water instead of before the oxygenation.
- the feed line 71 with the metering device 70 is not connected to the tank 26 but to the container 54.
- an electronic water flow meter corresponding to the counter 24 is connected to the line 51, to which the signal line 72 is then to be connected.
- Sodium pangamate is then added to the oxygen-enriched spring water in the container 54 in an amount that is proportional to the amount of water entering the container 54 and corresponds to the desired concentration of sodium pangamate. 19
- paths 22, 30 and 38, 40 are connected in parallel by opening valves 16, 16a, 28, 32, 42, 44 and 62 and closing valve 34.
- opening valves 16, 16a, 28, 32, 42, 44 and 62 are connected in parallel by opening valves 16, 16a, 28, 32, 42, 44 and 62 and closing valve 34.
- the desired oxygen concentration in the finished mixture is lower, for example 30 mg / l, it may be sufficient to continuously only in the stage comprising the pump 36, the mixing unit 46, the rotary nozzle 38 and the pipe system 40 in Be ⁇ drive to take what is possible by shutting off valves 28, 32, 34 and 16 and opening valves 62 and 42.
- the pump 36 must then of course generate the full water pressure.
- the outputs of the pumps 10 and 36 can be regulated and can be set as a function of the desired oxygen concentration and / or the type of liquid being treated.
- valve 34 and the valve 62 can be closed and the valves 28, 32 and 44 opened the first pump 10, the mixing unit 20 and the path 22, 30 take over the preparation of the mixture alone. Maintenance or repair work on the system can therefore be carried out without interrupting the continuous operation.
- the indicated oxygen concentration can have a scatter of plus or minus 5 mg / 10.
- FIG. 8 shows, for the units 20, 22 and 30 that are functionally shown in FIG. 7, as a concrete embodiment, a mixing unit 120 to which a rotary nozzle 140 is connected on the downstream side.
- the rotary nozzle 140 is connected to cylindrical coils 180, the axis 182 of which runs perpendicular to the flow direction 100 of the water supplied to the mixing unit 120.
- the longitudinal axes of the mixing unit 120 and the rotary nozzle 140 are aligned with the flow direction 100.
- the oxygen line opens into the interior of the body in its cylindrical body 122 (FIG. 9) via a connecting piece 125.
- the direction of flow of the liquid through the body 122 is indicated at 126.
- a front plate is inserted on the upstream side of the mouth of the gas feed pipe 124 and a rear plate 123 with the wall of the body 122 is sealingly inserted to the mouth of the gas feed pipe 124.
- the front plate has a central through-bore 125 and at about half the radius. 21
- the rear plate 132 has through bores which are axially aligned with the through bores 125 and 127, but have a somewhat smaller diameter, as indicated by the central through bore 128 and one of the outer through bores 129 in FIG. 10.
- a mixing nozzle 130 is inserted, the individual parts of which are shown in FIGS. 11 and 12. 9 shows only one of the seven mixing nozzles.
- Each mixing nozzle has a head part 132 with a central channel 133 which extends through the head part in the liquid flow direction and tapers slightly conically in a central section 134.
- the head part 132 can be screwed sealingly into the upper part of a nozzle shaft 135 by means of thread 131.
- the upper part 137 of the nozzle shaft is adjoined in the flow direction by an intake section with openings 136, 138, 139 drilled radially through the wall of the nozzle shaft 135.
- the channel which axially penetrates the nozzle shaft 135 and is designated overall by 140 tapers at a section 142 which merges into a cylindrical narrowed section 144 in the direction of flow.
- the channel 140 then widens to the outlet end 145 from the nozzle shaft 135. If the head part 132 is screwed into the upper part 137, 22
- the mixing nozzle 130 is inserted into the two through bores 125, 128 such that the center line 146 of the channel 140 is aligned with the axis 125 of the body 122 or is parallel to it when the mixing nozzle 130 is inserted into one of the other pairs of through bores approximately 127, 129 in the plates 121, 123.
- the body 122 flows through the mixing unit 120 in the direction 126 of water of 12 bar, this is pressed through the mixing nozzle 130, oxygen being sucked into the intermediate space 128 between the front plate 121 and the rear plate 123 from the gas supply nozzle 124 and is drawn through the bores 136, 138, 139 into the liquid flowing through the lower part of the channel 140.
- the liquid (water) enriched with oxygen in this way leaves the body 122 through its outlet connection 129.
- the inlet flange 152 of a rotary nozzle 150 is axially aligned with the outlet flange 129 of the mixing unit 120.
- the rotary nozzle has an axial channel 154 passing through it, which initially has the same cross-section as the outlet from the mixing unit 120.
- the channel 154 is reduced in cross-section and houses a rotary body 160 there.
- the rotary body is in 14 is shown schematically and designated 162.
- the rotating body 162 has several spiral paths 161, 163, 165, 167, the radius of which decreases in the direction of flow 151.
- the liquid flowing through the rotary nozzle 150 leaves it via the outlet channel 155, in 23
- the liquid flowing into the rotary nozzle 150 essentially axially into the channel 154 receives a deflection of its flow direction from a purely axial into a spiral flow through the rotary body 162, so that the liquid leaves the outlet 155 rotatingly and enters the pipe coil 180 in a rotating manner. A particularly intimate mixing of the liquid is thereby achieved.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Hydrology & Water Resources (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU46653/96A AU4665396A (en) | 1995-02-13 | 1996-02-13 | Non-alcoholic drink, the use thereof and a process for producing the drink |
DE19680075T DE19680075D2 (de) | 1995-02-13 | 1996-02-13 | Nichtalkoholisches Getränk, seine Verwendung sowie Verfahren und Vorrichtung zur Herstellung des Getränks |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19504706 | 1995-02-13 | ||
DE19504706.0 | 1995-02-13 | ||
DE19521015.8 | 1995-06-12 | ||
DE19521015 | 1995-06-12 | ||
DE19529955A DE19529955C1 (de) | 1995-02-13 | 1995-08-14 | Tafelwasser, Heilwasser oder dergleichen nicht alkoholisches Getränk |
DE19529955.8 | 1995-08-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996025057A1 true WO1996025057A1 (de) | 1996-08-22 |
Family
ID=27214831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/000595 WO1996025057A1 (de) | 1995-02-13 | 1996-02-13 | Nichtalkoholisches getränk, seine verwendung sowie verfahren und vorrichtung zur herstellung des getränks |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4665396A (de) |
DE (1) | DE19680075D2 (de) |
WO (1) | WO1996025057A1 (de) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6049775A (ja) * | 1983-08-29 | 1985-03-19 | Sanyuu Shoji Kk | 栄養食品の製造法 |
WO1988006411A1 (en) * | 1987-02-27 | 1988-09-07 | Mester-Coop Éklv | Process for producing and selling drinks saturated with molecula oxygen |
US4874509A (en) * | 1987-04-24 | 1989-10-17 | Donald Bullock | Oxidation saturation device |
DE3940389A1 (de) * | 1989-12-06 | 1991-06-13 | Abolghassem Prof Dr M Pakdaman | Therapeutisches mittel |
DE4226260C1 (de) * | 1992-08-08 | 1994-01-20 | Granini Gmbh | Verfahren zur Herstellung eines trinkbaren Kleieextraktes |
WO1995032796A1 (de) * | 1994-05-26 | 1995-12-07 | Dariush Behnam | Verfahren und vorrichtung zur anreicherung von sauerstoff in trinkbaren, wässrigen flüssigkeiten, insbesondere trinkwasser |
DE19529955C1 (de) * | 1995-02-13 | 1996-04-18 | Dariush Behnam | Tafelwasser, Heilwasser oder dergleichen nicht alkoholisches Getränk |
-
1996
- 1996-02-13 WO PCT/EP1996/000595 patent/WO1996025057A1/de active Application Filing
- 1996-02-13 AU AU46653/96A patent/AU4665396A/en not_active Abandoned
- 1996-02-13 DE DE19680075T patent/DE19680075D2/de not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6049775A (ja) * | 1983-08-29 | 1985-03-19 | Sanyuu Shoji Kk | 栄養食品の製造法 |
WO1988006411A1 (en) * | 1987-02-27 | 1988-09-07 | Mester-Coop Éklv | Process for producing and selling drinks saturated with molecula oxygen |
US4874509A (en) * | 1987-04-24 | 1989-10-17 | Donald Bullock | Oxidation saturation device |
DE3940389A1 (de) * | 1989-12-06 | 1991-06-13 | Abolghassem Prof Dr M Pakdaman | Therapeutisches mittel |
DE4226260C1 (de) * | 1992-08-08 | 1994-01-20 | Granini Gmbh | Verfahren zur Herstellung eines trinkbaren Kleieextraktes |
WO1995032796A1 (de) * | 1994-05-26 | 1995-12-07 | Dariush Behnam | Verfahren und vorrichtung zur anreicherung von sauerstoff in trinkbaren, wässrigen flüssigkeiten, insbesondere trinkwasser |
DE19529955C1 (de) * | 1995-02-13 | 1996-04-18 | Dariush Behnam | Tafelwasser, Heilwasser oder dergleichen nicht alkoholisches Getränk |
Non-Patent Citations (3)
Title |
---|
J.E.F.REYNOLDS ET AL.: "Martindale The Extra Pharmacopoeia", 1989, THE PHARMACEUTICAL PRESS, LONDON,U.K., XP002006995 * |
L.J.MACHLIN: "Handbook of Vitamins,second edition", 1990, MARCEL DEKKER, NEW YORK,N.Y., XP002006996 * |
PATENT ABSTRACTS OF JAPAN vol. 009, no. 180 (C - 293) 25 July 1985 (1985-07-25) * |
Also Published As
Publication number | Publication date |
---|---|
AU4665396A (en) | 1996-09-04 |
DE19680075D2 (de) | 1998-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3789576T2 (de) | Verwendung von Inositol-Triphosphat zur Behandlung von Metallvergiftung. | |
DE2321722A1 (de) | Verfahren zum behandeln von abwasser | |
DE3603900A1 (de) | Trinkwasserreinigungseinrichtung | |
EP0613688A1 (de) | Verfahren zur Bereitung von bicarbonathaltigen Dialysierflüssigkeiten für die Hämodialyse | |
DE102005053358A1 (de) | Vorrichtung zur gesteuerten Bereitstellung von Ozon | |
DE69634404T2 (de) | Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben | |
DE60132610T2 (de) | Verfahren zur minderung von ammoniak aus tierdung, eine anlage zur ausübund des verfahrens und eine anwendung dieser anlage | |
DE9420518U1 (de) | Vorrichtung zur Anreicherung von Sauerstoff in trinkbaren, wässrigen Flüssigkeiten, insbesondere Trinkwasser | |
EP2558192B1 (de) | Tauchreaktor für die zugabe von chlorgas oder chlordioxid in wasser | |
DE19529955C1 (de) | Tafelwasser, Heilwasser oder dergleichen nicht alkoholisches Getränk | |
DE102006028172A1 (de) | Verfahren und Vorrichtung zur Elimination von Arsen aus Wasser | |
WO1996025057A1 (de) | Nichtalkoholisches getränk, seine verwendung sowie verfahren und vorrichtung zur herstellung des getränks | |
WO2002009732A2 (de) | Verfahren und vorrichtung zur anreicherung und stabilisierung von konjugierten oestrogenen aus stutenharn | |
EP2609041A1 (de) | Vorrichtung und verfahren zur behandlung von flüssigkeiten mittels ozon | |
DE3902626C2 (de) | Verfahren zur biologischen Abwasserreinigung | |
EP0974682A1 (de) | Verfahren zur chemischen Behandlung von Metalloberflächen und dazu geeignete Anlage | |
DE3923480A1 (de) | Verfahren und vorrichtung zum anreichern von fluessigkeiten mit gas | |
DE10355400A1 (de) | Multikomponenten Mineralstoffpräparate und Verfahren zur Herstellung von Multikomponenten-Mineralstoffpräparaten | |
DE102006042804A1 (de) | Vorrichtung und Verfahren zur Trinkwasseraufbereitung sowie Trinkwässer | |
DE3942229C2 (de) | ||
DE2304705C2 (de) | Diätetische Mineralergänzungszubereitung | |
EP0000515B1 (de) | Verfahren zum Abtrennen von Schwefeldioxyd, aus einem Gasstrom und Anlage zur Durchführung des Verfahrens | |
EP0386560A1 (de) | Verfahren zur biologischen Phosphatelimination | |
DE2843074A1 (de) | Verfahren zur regelung und/oder steuerung einer biologischen klaeranlage | |
Miltimore et al. | Copper storage in the livers of cattle supplemented with injected copper and with copper sulfate and chelated copper |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996902267 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996902267 Country of ref document: EP |
|
122 | Ep: pct application non-entry in european phase | ||
REF | Corresponds to |
Ref document number: 19680075 Country of ref document: DE Date of ref document: 19981203 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19680075 Country of ref document: DE |